Investment

Zentalis is raising fresh capital via an underwritten public offering to fund trials and pre-commercial activities for its WEE1 inhibitor azenosertib in ovarian cancer.

Teva Pharmaceutical is issuing EUR and USD senior notes via Dutch finance subsidiaries, with proceeds earmarked primarily for early redemption of existing notes.

The NASDAQ-listed MWA device maker posted $9.9m in first-half revenue, with the US now accounting for 27% of sales versus under 2

AMS posted 19% year-on-year Q2 revenue growth to $8.4m, led by a 40% surge in direct patient services across its US and

S&P's upgrade to BBB- means Teva now holds investment-grade ratings from all three major agencies, capping a multi-month credit rehabilitation.

The NASDAQ-listed RNAi oncology biotech will use net proceeds to advance its Phase 2/3 SIL204 trial in locally advanced pancreatic cancer.

NorthStrive Biosciences will test probiotic candidates EL-22 and EL-32 in a live-mouse microgravity study under a non-binding deal with Australia's

A late-stage development advance in Centessa's OX2R agonist pipeline triggers an $8.6 million payment to Nxera, which retains future milestone and royalty

Lumexa Imaging swung to a $2.7m net profit in Q2 2026 as advanced imaging volumes grew 6.8% and the company added its ninth

The HORIZON Phase 3 trial of pelacarsen failed its primary cardiovascular endpoint, but royalty backer Royalty Pharma says it still expects a modest positive return.

New modelling data links antibiotic disc exposure to clinical benefit, strengthening the rationale for PP353 as a targeted, non-opioid therapy for vertebrogenic lumbar

Kala Bio will be the sole US distributor of Virotek's ophthalmology genomic testing programme under a one-year deal effective 4 September 2026.

The CRISPR biotech drew an initial $75m at closing, with further tranches tied to milestones for its HAE gene-editing candidate lonvo-z.

The NASDAQ-listed healthcare group reported 29.7% revenue growth in H1 2026 and repaid an $8m convertible note twelve months ahead of schedule.

The Chinese battery maker says Model 32140 shipments doubled year-on-year as it targets India's fast-growing light electric vehicle market.

The Milan biotech signed a convertible loan with the EIB, covering half of its €40m plan to reach CE Mark and EU launch for REGENERA

The Israel-based dual-business company reported FDA IND clearance for its intraocular drug-delivery ring and positive preclinical data for its non-opioid pain

The Thousand Oaks biotech floated on Nasdaq in August 2026 and published NEJM data on its lead NaV 1.8 inhibitor onzotrigine in acute pain.

GSK gains worldwide rights outside Greater China to HMPL-A830, a novel antibody-targeted therapy conjugate, with $110m upfront and up to $1.295bn in

The San Carlos biotech reported preliminary proof of concept for ATTO-1310 in chronic pruritus and atopic dermatitis, with two Phase 2 studies planned for